Docquity deepens its strategic partnership with exMedio to scale into Japan, centering on its Ask Dx clinical AI assistant to advance Asian Healthcare Intelligence rooted in Clinical Intent.

Building on a 2025 relationship with exMedio’s Hipokura community and Hematology Pro, the collaboration expands from AI tool provision to joint clinical support and knowledge sharing in oncology.

The initiative aims to create Asian Healthcare Intelligence grounded in Clinical Intent, mapping doctors’ questions and knowledge needs at the point of care to guide education and clinical support.

The MOU foresees broader collaboration over time, including potential ties with universities and medical institutions, with rapid access to knowledge and faster learning for physicians as a priority.

Initial focus areas include oncology knowledge sharing and clinical support, with services developed based on feedback from Japanese physicians and future plans to involve universities and medical institutions.

The partnership envisions extended collaboration with universities and medical institutions and outlines that specific services and launch timing will be announced separately.

Executives emphasize accelerating physician access to knowledge, co-creating new clinical support, and expanding expertise from hematology to solid tumors through AI-enabled collaboration.

Ask Dx will be integrated into exMedio’s learning, peer consultation, and information-search platforms to fit seamlessly into daily clinical workflows and provide fast, context-relevant knowledge at the point of care.

Ask Dx will be embedded within exMedio’s learning, peer-consultation, and information-seeking environments to align with daily clinical routines and enable rapid access to information.

The integration aims to ensure Ask Dx supports learning and decision-making within exMedio’s communities by aligning with routine practice patterns.

Japan is a core market with established specialist communities; exMedio’s Hematology Pro already includes more than 60% of Japan’s hematologists, and the model will extend to solid tumors.

The partnership seeks to extend the Hematology Pro model, which already covers a majority of Japanese hematologists, to solid tumors as part of broader oncology coverage.